- Previous Close
0.00 - Open
103.52 - Bid 101.65 x 28000
- Ask 107.75 x 38500
- Day's Range
103.52 - 103.52 - 52 Week Range
96.68 - 140.32 - Volume
20 - Avg. Volume
95 - Market Cap (intraday)
24.157B - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
30.06 - EPS (TTM)
3.28 - Earnings Date May 6, 2025
- Forward Dividend & Yield 4.81 (4.88%)
- Ex-Dividend Date Dec 6, 2024
- 1y Target Est
--
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
www.coloplast.com16,628
Full Time Employees
September 30
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: CLPBF
View MorePerformance Overview: CLPBF
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLPBF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLPBF
View MoreValuation Measures
Market Cap
24.16B
Enterprise Value
27.80B
Trailing P/E
30.05
Forward P/E
25.51
PEG Ratio (5yr expected)
2.26
Price/Sales (ttm)
5.35
Price/Book (mrq)
9.50
Enterprise Value/Revenue
6.64
Enterprise Value/EBITDA
20.83
Financial Highlights
Profitability and Income Statement
Profit Margin
17.79%
Return on Assets (ttm)
9.54%
Return on Equity (ttm)
31.94%
Revenue (ttm)
27.45B
Net Income Avi to Common (ttm)
4.88B
Diluted EPS (ttm)
3.28
Balance Sheet and Cash Flow
Total Cash (mrq)
906M
Total Debt/Equity (mrq)
160.13%
Levered Free Cash Flow (ttm)
-377.25M